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Abstract The amyloid protein precursor (APP) of Alzheimer’s
disease can stimulate neurite outgrowth in vitro. The receptor
responsible for this effect has not been identified. Kunitz protease
inhibitor (KPI)-containing forms of APP bind to the low-density
lipoprotein receptor-related protein (LRP). As LRP may
regulate neurite outgrowth, we examined whether the effects of
APP are mediated by LRP. Inhibitors of LRP decreased neurite
outgrowth from chick sympathetic neurons. Most LRP ligands
(K2-macroglobulin, lactoferrin, and lipoprotein lipase) stimulated
outgrowth. However, in soluble form, the KPI-containing
APP751 was a weak inhibitor of outgrowth. In substrate-bound
form, both APP751 and APP695 (which does not bind to LRP)
stimulated outgrowth. Thus the effect of substrate-bound APP
on neurite outgrowth is not mediated by LRP.
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1. Introduction
In Alzheimer’s disease (AD), amyloid plaques contain a
protein, AL, derived from a larger L-amyloid precursor pro-
tein (APP) [1]. Di¡erential splicing of APP mRNA produces
major isoforms which either contain (APP751 and APP770) or
lack (APP695) a Kunitz protease inhibitor (KPI) domain [2^4].
A number of studies have shown that APP can stimulate
neurite outgrowth [5^7].
A recently discovered risk factor for late-onset AD is the O4
allele of the apolipoprotein E (apoE) gene [8]. ApoE is im-
portant for neurite outgrowth, an e¡ect that is mediated by
the low-density lipoprotein receptor-related protein (LRP) [9^
13]. KPI-containing forms of APP have also been shown to
bind to LRP [14]. These ¢ndings raise the possibility that
KPI-containing forms of APP may in£uence neurite out-
growth via LRP. In support of this hypothesis, Qiu et al.
[15] found that KPI-containing forms of APP more potently
stimulate neurite outgrowth than KPI-lacking forms, and
Diaz-Nido et al. [16] found that a peptide homologous to
the KPI domain induced neurite outgrowth.
The aim of this study was to examine the e¡ect of various
LRP ligands, including APP751, on neurite outgrowth from
chick sympathetic neurons. We show that the e¡ect of APP
in stimulating neurite outgrowth is not mediated via LRP.
2. Materials and methods
2.1. Materials
The 39-kDa receptor-associated protein (RAP) was prepared as
described by Williams et al. [17]. A⁄nity-puri¢ed anti-LRP antisera
R777 and R2999 were prepared as described by Kounnas et al. [18].
Anti-LRP antiserum R704 was raised against cytoplasmic LRP resi-
dues 4513^4524 conjugated to keyhole limpet haemocyanin, puri¢ed
over a Sepharose-peptide column, and heated at 56‡C for 60 min prior
to use. A peptide homologous to residues 136^166 of apoE3/E4 (Ac-
RLASHLRKLRKRLLRDADDLQKRLAVYQAGA-NH2) was syn-
thesized by Chiron-Mimotopes (Clayton, Australia). Putrescine, nerve
growth factor (2.5 S) and progesterone were from Sigma-Aldrich Pty.
Ltd. (Castle Hill, Australia). Insulin-transferrin-selenium-X growth
supplement was from Gibco-BRL (Grand Island, NY). Poly-L-lysine
(molecular weight 144 000) and K2-macroglobulin (K2M) were from
ICN Biomedicals Inc. (Seven Hills, Australia). K2M was activated by
incubation with 400 mM methylamine and then desalted against phos-
phate-bu¡ered saline (PBS) [19]. Bovine lipoprotein lipase (LPL), pre-
pared according to [20], was donated by Prof. W. Sawyer (University
of Melbourne, Australia). Recombinant APP and its fragments ex-
pressed in Pichia pastoris were puri¢ed as described in Henry et al.
[21]. APP/Factor IXa complexes were prepared as previously de-
scribed [14].
2.2. Culture of chick sympathetic neurons
E12 chick sympathetic neurons were cultured on 24-well plastic
dishes at 10 000 cells/well as described previously [22]. Compounds
were added 2 h after plating to allow time for cells to attach. For
experiments on the e¡ect of substrate-bound proteins, wells were
coated with 0.1 mg/ml polylysine followed by the protein of interest
(10 Wg/ml) [23]. Neurite length was measured by image-capture anal-
ysis as described [22]. Five ¢elds in each of 4 wells per treatment
group were examined. Routinely, 100^200 neurites were measured
per group. Di¡erences between groups were calculated by a one-
way analysis of variance and a two-tailed Student’s t-test.
3. Results
To examine whether LRP regulates neurite outgrowth from
chick sympathetic neurons, the e¡ect of LRP inhibitors was
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studied (Fig. 1). The 39-kDa receptor-associated protein
(RAP), two a⁄nity-puri¢ed antibodies raised against the ex-
tracellular domain of LRP (R777 and R2999), and a peptide
(apoE 136^166) homologous to the receptor-binding region of
apoE [24^28] caused a signi¢cant (P6 0.05) reduction in neu-
rite outgrowth. In contrast, a control antibody speci¢c for the
cytoplasmic domain of LRP (R704) did not inhibit neurite
outgrowth.
LRP ligands were tested for their e¡ects (Fig. 2). K2M (0.5^
3 Wg/ml or 0.7^3.9 nM) stimulated neurite outgrowth by 30^
40%. This e¡ect was still evident after activation with methyl-
amine, which removes its protease inhibitor activity [19],
thereby demonstrating that the e¡ect was not due to inhibi-
tion of an endogenous protease. Similarly, lipoprotein lipase
(LPL, 15^50 Wg/ml or 300^1000 nM) and lactoferrin (3^30 Wg/
ml or 40^400 nM) also stimulated outgrowth. The concentra-
tions of these ligands required to stimulate neurite outgrowth
were similar to those reported previously as being necessary
for binding to LRP [29,30].
To examine whether the neurite outgrowth-promoting ef-
fects of APP on chick sympathetic neurons are mediated by
LRP, P. pastoris-expressed human APP695 and APP751 were
tested for their e¡ects (Figs. 2 and 3). APP751 produced a
weak (20%) inhibition of neurite outgrowth at the highest
concentration tested (7 Wg/ml, V80 nM). With the addition
of Factor IXa, which promotes binding of APP to LRP [14],
neurite length was 70% of control values. Soluble APP695 did
not inhibit neurite outgrowth, supporting the view that the
e¡ect was mediated by LRP. In contrast, substrate-bound
APP stimulated outgrowth (Fig. 3, right). There was no di¡er-
ence between the e¡ect of APP695 and APP751, indicating that
this e¡ect was not mediated via LRP.
To identify regions of APP which could be involved in
neurite outgrowth promotion, we examined three fragments
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Fig. 1. E¡ect of LRP inhibitors on neurite length using isolated E12
chick sympathetic neurons. The ¢gure shows quantitative image-cap-
ture analysis of neurite length [22]. Values are means þ S.E.M., with
the mean control value = 100% (approximately 100 Wm). Asterisks
indicate signi¢cantly di¡erent from controls (P6 0.05) as determined
by a Student’s t-test. Cultures contained 350 Wl of growth medium
to which was added 5 Wl PBS (Control), RAP (3 Wg in 5 Wl PBS),
R777 anti-LRP antibody (1 Wg in 5 Wl PBS), R2999 anti-LRP anti-
body (1 Wg in 5 Wl PBS), R704 anti-LRP antibody (1 Wg in 5 Wl
PBS) or apoE136ÿ166 peptide (25 Wg in 5 Wl).
Fig. 2. E¡ect of LRP ligands on neurite length, using isolated E12 chick sympathetic neurons. Values are means þ S.E.M. One-way analysis of
variance on all curves indicated a signi¢cant e¡ect for each ligand (P6 0.05). Asterisks show values signi¢cantly di¡erent from controls as
assessed by a Student’s t-test. Cultures contained 350 Wl of growth medium to which were added di¡erent concentrations of native K2M (b),
activated K2M (a), lipoprotein lipase (LPL), lactoferrin, or APP751.
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of APP for their e¡ects in substrate-bound form (Fig. 3,
right). Neurite length was signi¢cantly increased by APP
(18^194) and by APP (316^447), but APP (505^611) did not
stimulate outgrowth.
4. Discussion
This study demonstrates that (i) several ligands of LRP
(K2M, lactoferrin, LPL) can stimulate neurite outgrowth
from chick sympathetic neurons; (ii) soluble APP751 is a
weak inhibitor of neurite outgrowth in the same system;
and (iii) the ability of substrate-bound APP to stimulate neu-
rite outgrowth is not due to an interaction with LRP. Instead
two domains in APP that were previously shown to interact
with heparan sulfate proteoglycans (HSPGs) (APP 18^194,
APP 336^447) [31^33], may contribute to the stimulatory ef-
fects of substrate-bound APP, suggesting the possibility that a
cell-surface HSPG could be an APP receptor.
The e¡ects of RAP, K2M and anti-LRP antibodies on neu-
rite outgrowth are similar to those previously reported [13,19].
Other reports also indicate that LRP has important develop-
mental functions [9^12,34]. The mechanism by which LRP
ligands, and especially apoE, regulate neurite outgrowth is
unclear. It has been suggested that the e¡ects of apoE on
neurite outgrowth are due to the increased availability of lip-
ids for outgrowth [9,35]. Howeve,r such a mechanism does not
explain why other LRP ligands can stimulate outgrowth.
The reasons why soluble APP751 di¡ered from other LRP
ligands is also unclear. APP751 may inhibit neurite outgrowth
by an action which is independent of its binding to LRP.
Alternatively, APP751 and RAP may interact with LRP at a
site which is distinct from sites used by other ligands.
The role of LRP in the pathogenesis of AD needs to be
clari¢ed. Several LRP ligands have been found around amy-
loid plaques [36,37]. However, the role of these ligands in
plaques is unknown. The observation that APP751 mRNA
expression is higher around plaques [38] raises the possibility
that interactions between APP and LRP could disturb the
trophic environment of the plaque, contributing to the abnor-
mal neuritic pathology.
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